Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
01
Overview
DeHydr8's DehydraTECH platform, a self-emulsifying drug delivery system (SEDDS), has demonstrated significant bioavailability improvements for cannabinoids in clinical studies. In a randomized, placebo-controlled, double-blind study, the technology delivered over 300% more CBD to blood at the 30-minute mark compared to a control formulation[2]. Results suggest the technology delivered over 900% more CBD to the blood in the first 30 minutes compared to GW Pharmaceuticals' Epidiolex formulation on a concentration-adjusted basis[2].
- Modalities
- Drug delivery system
- Industry
- Biotech
Beyond the preview
Go deeper on DeHydr8.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DeHydr8.